Erik Ostrowski

CIK: 0001762507

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)3 (60.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (40.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

AKBA

Akebia Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (5 total)

AKBA
Akebia Therapeutics, Inc.
Jun 29, 2026
Sale(S)
Direct
56K shares at avg. $1.11$62K
AKBA
Akebia Therapeutics, Inc.
Feb 2, 2026
Sale(S)
Direct
35K shares at avg. $1.39$49K
AKBA
Akebia Therapeutics, Inc.
Jan 30, 2026
Award(A)
Direct
204K shares-
AKBA
Akebia Therapeutics, Inc.
Jun 30, 2025
Sale(S)
Direct
41.3K shares at avg. $3.67$152K
AKBA
Akebia Therapeutics, Inc.
Jan 31, 2025
Award(A)
Direct
194.9K shares-

		Type	Shares	Price		Ownership
Jun 29, 2026	AKBA Akebia Therapeutics, Inc.	Sale(S)	56,019	$1.11	$62,181	Direct
Feb 2, 2026	AKBA Akebia Therapeutics, Inc.	Sale(S)	34,951	$1.39	$48,582	Direct
Jan 30, 2026	AKBA Akebia Therapeutics, Inc.	Award(A)	204,000	-	$0	Direct
Jun 30, 2025	AKBA Akebia Therapeutics, Inc.	Sale(S)	41,314	$3.67	$151,622	Direct
Jan 31, 2025	AKBA Akebia Therapeutics, Inc.	Award(A)	194,900	-	-	Direct

1-5 of 5 transactions

About Ostrowski Erik

Ostrowski Erik (SEC CIK 0001762507) files insider reports with the SEC as SVP, CFO, CBO & Treasurer of Akebia Therapeutics, Inc. (AKBA).

Signal8 holds 5 ownership filings by Ostrowski Erik, all Form 4s, filed between Feb 4, 2025 and Jul 1, 2026. Those filings report 5 transactions, from Jan 31, 2025 to Jun 29, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Ostrowski Erik's filings is in CAMBRIDGE, MA.

Recent filings by Ostrowski Erik

Jun 29, 2026: Open-market sale of AKBA shares (Form 4, code S).
Feb 2, 2026: Open-market sale of AKBA shares (Form 4, code S).
Jan 30, 2026: Grant or award of AKBA shares (Form 4, code A).
Jun 30, 2025: Open-market sale of AKBA shares (Form 4, code S).
Jan 31, 2025: Grant or award of AKBA shares (Form 4, code A).

Other insiders filing for Akebia Therapeutics, Inc. (AKBA)

Butler John P., CEO and President
Wolf Myles, Director
Smith Cynthia, Director
ROGERS MICHAEL W, Director
FRIESON RON, Director
ZUMWALT LEANNE M, Director

How to read Form 4 transaction codes